Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease.
Saraf SL, Hagar RW, Idowu M, Osunkwo I, Cruz K, Kuypers FA, Brown RC, Geib J, Ribadeneira MD, Schroeder P, Wu E, Forsyth S, Kelly PF, Kalfa TA, Telen MJ.
Saraf SL, et al. Among authors: wu e.
Blood Adv. 2024 Apr 19:bloodadvances.2023012467. doi: 10.1182/bloodadvances.2023012467. Online ahead of print.
Blood Adv. 2024.
PMID: 38640200